Jean-Valère M.
- Country
- France
- Department
- Hématologie
Research Overview
- Phase 3 Study of Idarubicin, Daunorubicin, Cytarabine, and Mycophenolic Acid in Acute Myeloid Leukemia Patients Aged 18-60
- Minimal Residual Disease-Adapted Strategy in Multiple Myeloma: Evaluation of Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone in Transplant-Eligible Patients
- Phase III Randomized Study of Continuous vs. Fixed Duration Daratumumab, Lenalidomide, and Dexamethasone Therapy in Relapsed Multiple Myeloma
Data & Insights
Has run more than one trial at 85 of 257 partner sites.
Specializations
Acute Leukemia and Myeloid Malignancies
Jean-Valère MALFUSON is involved in clinical research in acute myeloid leukemia, with attention to FLT3-mutated AML, IDH1-mutated AML, NPM1-mutated AML, and myelodysplastic syndrome. The portfolio also includes work in chronic myelogenous leukemia in accelerated or blast phase and other onco-hematology settings.
- Relapsed and refractory AML
- Mutation-directed myeloid therapy
- Myelodysplastic syndromes
- Advanced chronic myeloid leukemia
His research activity reflects a strong therapeutic focus on targeted and immunologic approaches in hematologic cancer care, including disease control in both newly diagnosed and resistant settings.
Acute Lymphoblastic Leukemia and Transplant-Related Care
His clinical interests extend to acute lymphoblastic leukemia, including B-cell and T-cell ALL, as well as transplant-associated management in allogeneic hematopoietic stem cell transplantation. This area also includes post-transplant complications such as pure red cell aplasia and supportive strategies around transplant recovery.
- Frontline ALL therapy
- Allogeneic stem cell transplantation
- Post-transplant marrow recovery disorders
- Immune-mediated hematologic complications
The therapeutic landscape includes interest in refining transplant integration and post-transplant disease control in adult leukemia.
Multiple Myeloma and Plasma Cell Disorders
Jean-Valère MALFUSON is active in multiple myeloma research, including treatment of relapsed disease, frail patients with newly diagnosed myeloma, and post-transplant maintenance strategies. His work also touches minimal residual disease assessment and response-adapted treatment in plasma cell disorders.
- Relapsed multiple myeloma
- Frail newly diagnosed myeloma
- Post-autograft maintenance
- MRD-guided treatment strategies
This domain highlights a sustained interest in optimizing depth of remission and long-term disease control in plasma cell malignancies.
Solid Tumors, Lung Cancer, and Gastrointestinal Oncology
His research also includes non-small cell lung cancer, colon carcinoma, and broader solid tumor care, with attention to advanced disease and treatment after targeted therapy. Additional interests include brain metastases with radionecrosis and cancer-related thrombotic risk.
- Non-small cell lung cancer
- Colon cancer
- Brain metastases and radionecrosis
- Cancer-associated thrombosis
These studies indicate involvement in therapeutic innovation across thoracic, gastrointestinal, and neuro-oncology-related complications.
Infectious, Inflammatory, and Thrombotic Conditions
Jean-Valère MALFUSON contributes to research in chronic pulmonary aspergillosis, Mycobacterium avium complex lung disease, giant cell arteritis, and acute venous thromboembolism. The portfolio also includes prevention of infectious complications during hematopoietic stem cell transplantation.
- Chronic pulmonary aspergillosis
- Mycobacterial lung infection
- Giant cell arteritis
- Venous thromboembolism prevention
His therapeutic interests cover both immune-mediated disease and complication prevention in highly vulnerable hematology and oncology populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.